knowledge -WSS

knowledge

author：focus 2025-09-30 00:49:17 - browse：24154

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： HIV drugs protect against transmission, even in unprotected sex

explore

WSS

Information blocking fines are now fair game in health care

The unintended consequences of overturning Roe v. Wade

FDA panel to weigh safety of artificial wombs for preterm births

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ASCO: AstraZeneca says CAR

leisure time

knowledge

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Cord blood banking comes at a high cost to babies

The high cost of giving birth even with insurance

Why the drug industry's warnings on the IRA's impact fall short

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

BMI, flaws aside, is found to be useful estimate of body fat in youth

Medical leaders decry Supreme Court decision on affirmative action

Fed up with FDA, ALS advocates consider a take

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

explore

Information blocking fines are now fair game in health care

FDA weighs limits of animal data in assessing artificial wombs

Ionis drug prevents swelling attacks due to hereditary angioedema

Grad students accuse University of California of wage theft

David Liu startup to focus on CRISPR delivery

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

entertainment

explore

Wikipedia

Wikipedia